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Abstract: Tivozanib is an oral selective vascular endothelial growth factors receptor
(VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines
Agency for the treatment of previously untreated patients with metastatic renal cell carci-
noma (mRCC) as well as for those patients with disease progression during or after cytokine
therapy. Nowadays, in ﬁrst-line and second-line treatment of mRCC, there is an abundance
of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review
focusses on the role of tivozanib with respect to patient selection and future perspectives
in this fast-changing landscape.
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Introduction
Renal cell cancer (RCC) is the 7th most common cancer in the UK with an increasing
incidence of up to 12,600 new cases per year in 2015.1 Being related to lifestyle factors
such as obesity, smoking, hypertension, and increasing age, RCC has been one of the
fastest increasing cancers in the past decades.2 Males are more frequently affected than
females and the peak incidence is at 60–80 years. The most frequently diagnosed
histological subtype is clear cell RCC (80%) followed by papillary (10–15%) and
chromofobe (5–10%) RCC.Due to its location, RCC initially goes often unnoticed, and
as a result, most patients present with either locally advanced or metastatic disease.
About one-third of patients presenting with RCC have metastatic disease (metastatic
renal cell carcinoma (mRCC)) at their time of diagnosis.3 In contrast to the situation of
locally advanced disease, where a radical nephrectomy is a potentially curative option,
performing a nephrectomy in case of metastatic disease does not seem to be the golden
standard anymore.4 Before considering a systemic treatment for mRCC, it is crucial to
consider that in many patients mRCC can have a very indolent course, meriting close
observation as a viable and rational ﬁrst-line treatment option. As a general ﬁnding,
mRCC is insensitive to either hormonal and cytotoxic therapies, but blocking the
intracellular signalling activity of vascular endothelial growth factors receptors
(VEGFR) through tyrosinekinase inhibitors (TKI) and thereby inhibiting angiogenesis
has been shown to be an effective standard of care.5 Inhibiting the mammalian target of
rapamycin (mTOR), a kinase protein which is important in signal transduction of
factors associated with angiogenesis and proliferation, has for years been considered
another rational target for treatment, but nowadays this paradigm is rapidly losing
terrain. The standard of care in advanced or mRCC in essence depends on the risk
stratiﬁcation according to the Memorial Sloan Kettering Cancer Center and/or
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International Metastatic RCC Database consortium
criteria.6,7 Until recently, ﬁrst-line therapy in patients with
good or intermediate prognosis mRCC usually consisted of
a VEGFR targeting TKI such as pazopanib or sunitinib or
alternatively the combination of bevacizumab with IF8N-
α.8–11 For patients with poor prognosis mRCC, ﬁrst-line
treatment with the mTOR inhibitor temsirolimus was recom-
mended, even though sunitinib, sorafenib, and pazopanib
were frequently used alternatives.12 Recently, a large rando-
mized phase III study, however, has unequivocally shown
that the combination of nivolumab and ipilimumab was
superior to sunitinib with regard to the primary end point
overall survival in patients with intermediate- and poor-risk
mRCC, but not in good-risk patients.13 Based on this study,
the updated ESMO 2019 guidelines prefer this combination
as ﬁrst-line treatment in patients with intermediate- and poor-
risk mRCC.14 Whether the recent publications of the combi-
nation of either pembrolizumab or avelumab with the TKI
axitinib will again change the current (and seemingly ever-
moving) landscape of ﬁrst-line treatment of mRCC remains
to be established.15, 16Second-line treatment in patients with
progressive disease either during or after ﬁrst-line treatment
depends on a variety of factors. For patients with disease
progression during or after ﬁrst-line cytokine
treatment, second-line therapy usually consists of single-
agent TKI treatment, where sorafenib, tivozanib, or axitinib
can be considered.11,14,17–19 In case of disease progression
during or after ﬁrst-line TKI treatment, a variety of treatment
options is available, whereby either nivolumab or cabozanti-
nib have compelling data regarding effects on overall
survival.20,21 If these options cannot be considered, lenvati-
nib combined with everolimus could be an option, albeit that
their effect on the primary end point progression-free survi-
val is based upon randomized phase II clinical data.18,22
There is no standard recommendation for third-line treat-
ment; hence, these patients should preferably be enrolled
into clinical trials to create more evidence for TKI or immu-
notherapy in third or fourth line.23–25 Even though the prog-
nosis for patients with advanced or mRCC has signiﬁcantly
improved over the last one to two decades following the
introduction of the above-mentioned treatment options,
there still remains a need for more effective and (better)
tolerable treatment options in the various lines of treatment.
Tivozanib
In August 2017, the European Medicines Agency (EMA)
approved tivozanib, a highly selective VEGFR TKI for
treatment of mRCC patients who were previously
untreated or in whom the disease progression occurred
after one prior treatment with cytokine therapy.26
Mode of action
Functional preclinical trials with tivozanib showed
a selective and potent inhibition of VEGF tyrosine kinase
receptors 1, 2, and 3.27 The VEGF signaling pathway
plays an important role in physiological and pathological
conditions such as endothelial cell proliferation, migration,
and survival and thus angiogenesis, which facilitates tumor
growth and the formation of metastases. There are three
VEGF receptors (1, 2, and 3) and ﬁve VEGF ligands (A,
B, C, D, and placental growth factor). Each ligand exhibits
distinct but overlapping binding proﬁles for the three
receptors. VEGFR-1 is critical for vessel morphogenesis
and modulation of endothelial cell proliferation, whereas
VEGFR-3 promotes vascular network formation and
endothelial sprouting. The predominant receptor for
endothelial cell proliferation and migration however is
VEGFR-2. Most tumors produce VEGF, and in preclinical
models, tumor growth was signiﬁcantly reduced through
inhibition of VEGF-induced angiogenesis.28 As each
VEGFR plays an important and different role in cancer
angiogenesis, it may be critical to block all three VEGFRs.
Tivozanib is a TKI with the capacity to inhibit all three
VEGFRs.
Trials with Tivozanib
Eskens et al and Niwakawa et al performed phase I clinical
studies in patients with advanced solid tumors and showed
that 1.5 mg of tivozanib once daily in an on/off treatment
schedule was well tolerated.29,30 The best overall response
observed in these studies was stable disease, sometimes
lasting over 6 months. The most frequently observed
severe adverse events (AEs) (grade ≥3) included hyperten-
sion, proteinuria, hand-foot skin reaction, fatigue, diarrhea,
and hepatic function abnormalities.
Subsequently, clinical activity of tivozanib in patients
with mRCC was demonstrated in a phase II study of
Nosov et al.31 Patients with mRCC without prior targeted
therapy received tivozanib 1.5 mg orally for 3 weeks
followed by 1 week off-drug. The overall response rate
(ORR) was 24% and the median progression-free survival
(PFS) was 11.7 months. Most patients (83%) had a clear
cell histology, and in patients with clear cell histology who
had previously undergone a nephrectomy, the ORR was
30% and a median (PFS) of 14.8 months was observed.
Rodenburg and Eskens Dovepress
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Subsequently, Motzer et al conducted a large interna-
tional open-label, randomized, multicenter phase III trial
comparing the efﬁcacy and tolerability of tivozanib versus
that of sorafenib in patients with clear cell mRCC.
Additional inclusion criteria were an ECOG performance
status (PS) of 0–1, a prior nephrectomy, and 0–1 prior
lines of treatment, which were not to have consisted of
inhibitors of mTOR or VEGF.19 The primary end point of
this study, which enrolled 517 patients, was PFS. The
study groups were well-balanced, except for PS (tivozanib
group 45% of the patients had a PS of 0, while in the
sorafenib group this was 54%, p=0,035). Patients were
stratiﬁed for either 0 or 1 previous line of treatment; in
both groups, 70% of the patients were treatment naive. In
the intention to treat population, the primary end point
median PFS was 11.9 months (95%-CI: 9.3–14.7) in the
tivozanib group and 9.1 months (95%-CI: 7.3–9.5) in the
sorafenib group (HR: 0.797 [95%-CI: 0.639–0.993];
p=0.042)). In the prospectively deﬁned subgroup of
patients without previous treatment, PFS was 12.7 months
(95%-CI: 9.1–15) in the tivozanib group and 9.1 months
(95%-CI: 7.3–10.8) in the sorafenib group (HR: 0.756
[95%-CI: 0.580–0.985]; p=0.037). The median OS,
a secondary end point in this study, was not signiﬁcantly
different (29.3 vs 28.8 months, HR 1.245, p=0.105)
because crossover from sorafenib to tivozanib was allowed
and patients received more third-line therapy after sorafe-
nib than after tivozanib due to geographical reasons. AEs
more frequently observed with tivozanib than with sorafe-
nib were dysphonia and hypertension, whereas patients
treated with sorafenib experienced more hand-foot skin
reaction and diarrhea. Overall, patients receiving tivozanib
needed less dose reduction due to AEs than patients
receiving sorafenib.
Tivozanib as treatment option
As mentioned, the landscape for patients with mRCC
has changed tremendously over the last 10–15 years,
with VEGFR-directed TKIs, inhibitors of mTOR, and
more recently immunotherapy as emerging treatment
options. However, despite this continuously expanding
plethora of available treatment options, mRCC is still
not a curable disease. Treatment focuses on extending
survival while maintaining the quality of life.
Unfortunately, all treatment options have side effects
which often force adjustments or discontinuation of
treatment. Therefore, and again taking into consideration
that in some patients mRCC can run an indolent course
over prolonged periods of time, meriting a period of
observation before systemic treatment indeed should be
considered, a careful judgment of efﬁcacy and toxicity
should be made before any treatment is initiated.
Nowadays, in ﬁrst- and second-line treatment of
mRCC, there is an abundance of options. The available
evidence for immunotherapy in ﬁrst and second line and
cabozantinib in second line caused a paradigm shift.
However, the VEGFR-directed TKIs such as sunitinib,
sorafenib, pazopanib, lenvatinib, axitinib, and tivozanib
are still viable and proven treatment options. Most of
these TKIs have been compared in randomized phase III
studies with either interferon alpha or placebo, with only
a limited number of randomized studies comparing two
TKIs.8,18,19,32 Therefore, evaluating their relative efﬁcacy
is difﬁcult. Side effects are mainly a class effect; hence, all
TKIs induce AEs but with different degrees of severity.
The side-effect proﬁle of the VEGFR selective TKI tivo-
zanib seems to differ somewhat from that of most of the
other TKIs and mainly consists of dysphonia and hyper-
tension, while the more cumbersome side effects such as
skin toxicities and hand-foot skin reactions were only
infrequently observed.19,30,31
It has been somewhat puzzling that although the rando-
mized phase III trial with tivozanib as ﬁrst- or second-line
treatment for patients with mRCC was already published in
2013, EMA only recently approved tivozanib for this indi-
cation. Probably, the fact that FDA rejected tivozanib for
this indication following the request for registration in the
USA in 2013 explains this delay. In the USA, a large ran-
domized phase III study comparing tivozanib to sorafenib
in patients with refractory mRCC has been closed for
accrual and ﬁrst results are expected to become available
in the next couple of months. It can be anticipated that if
results from this study are favorable, resubmission of tivo-
zanib to FDA could be pursued.
Perspectives
Despite the large and expanding arsenal of treatment
options, mRCC remains an incurable disease. This
prompts investigators to combine various classes of agents
in an attempt to improve treatment outcomes while main-
taining at least an acceptable quality of life. Within this
framework, tivozanib combination therapy with
Dovepress Rodenburg and Eskens
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temsirolimus has been explored, revealing that this combi-
nation could be safely given to patients with mRCC pre-
viously exposed to at least one line of VEGFR-directed
therapy.33 Even though conﬁrmed partial responses and
a high percentage of disease stabilization was observed,
no follow-up studies have been initiated. A single-arm
phase Ib/II study combining tivozanib with nivolumab
(TiNivo trial) has been closed for accrual and results are
also expected within the next couple of months
(NCT03136627).
Patient selection
Pending the FDA approval of tivozanib, treatment options
for metastatic renal cancer are emerging rapidly. With its
speciﬁc side-effect proﬁle of mainly hypertension and
hoarseness, tivozanib is a relatively mild and well-
tolerated TKI. Therefore, tivozanib might be an interesting
treatment option for patients who suffer from severe side
effects of other TKIs or have a decreased Karnofsky
Performance Score. Although immunotherapy is an emer-
ging treatment option for mRCC, not all patients are
eligible for this treatment. For instance, patients with
severe autoimmune disease are unsuitable for immunother-
apy. TKIs such as tivozanib therefore remain an important
treatment option. Furthermore, we eagerly await clinical
data on the effect of tivozanib in the third line.
Conclusions and future perspectives
Tivozanib is an oral selective VEGFR-TKI that has
demonstrated antitumor activity and effects on overall
survival in various studies in patients with mRCC. The
most common AEs are manageable hypertension and hoar-
seness. Recently, the EMA has approved tivozanib for the
treatment of previously untreated patients with mRCC as
well as for those patients who had disease progression
during or after cytokine therapy. Therefore, tivozanib has
now become another treatment option for these patients.
Because of the crowded and rapidly changing ﬁeld of
treatment options for patients with mRCC, further research
is ongoing to determine the role of tivozanib within this
ﬁeld. Special emphasis is currently put on the combination
of TKIs such as tivozanib and other yet approved options
for patients with mRCC, in particular, anti-PD-(L)1-direc-
ted monoclonal antibodies.
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